{"doi":"10.1016/j.jocn.2004.10.018","title":"Phase II study of two-weekly temozolomide in patients with high-grade gliomas","abstract":null,"journal":"Journal of Clinical Neuroscience","year":2006,"id":605073,"datarank":0.3958585994422889,"base_score":2.639057329615259,"endowment":2.639057329615259,"self_citation_contribution":0.3958585994422889,"citation_network_contribution":0.0,"self_endowment_contribution":0.3958585994422889,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1552690,"name":"Mark A. Rosenthal","orcid":null,"position":1,"is_corresponding":false},{"id":1552692,"name":"Anthony Dowling","orcid":null,"position":2,"is_corresponding":false},{"id":33785,"name":"Ross Jennens","orcid":"0000-0002-9872-997X","position":3,"is_corresponding":false},{"id":1552694,"name":"Anne-Marie Woods","orcid":null,"position":4,"is_corresponding":false},{"id":1552695,"name":"David Ashley","orcid":null,"position":5,"is_corresponding":false},{"id":1552699,"name":"Lawrence Cher","orcid":null,"position":6,"is_corresponding":false},{"id":1033039,"name":"Shirley Wong","orcid":"0000-0003-3810-6495","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Phase II study of two-weekly temozolomide in patients with high-grade gliomas","abstract":"Palliative chemotherapy has an increasing role in the management of recurrent high-grade gliomas. Temozolomide is a well-tolerated agent that results in objective responses and stabilisation of disease. Theoretically, temozolomide may be more effective when given in a prolonged schedule rather than the standard 5 days-monthly schedule. This Phase II study examined the efficacy and toxicity of temozolomide when given in a two-weekly schedule. Twenty-five patients received 150 mg/m2 temozolomide daily for seven days alternating with seven days of no treatment. One cycle of temozolomide was a total of two weeks treatment in every 28 days. Of the 25 evaluable patients, there was one complete response (4%), four partial responses (16%) and 10 patients had disease stablisation (40%). The progression free survival at 6 months was 56%. Two-weekly temozolomide was well tolerated with only four episodes of Grade 3 thrombocytopenia. Overall, two-weekly temozolomide is an active and well tolerated schedule, but does not appear to improve on the activity of temozolomide using the standard 5-day schedule.","is_dataset_classified":null,"base_score":2.639057329615259,"endowment":2.639057329615259,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"16356721","pmcid":null,"openalex_id":"https://openalex.org/W2019296828","authors":[],"funders":[],"total_grants":0,"fwci":0.1456,"citation_percentile":0.54594778,"influential_citations":0,"citation_trend":[{"year":2012,"count":3},{"year":2013,"count":1},{"year":2014,"count":1},{"year":2015,"count":1},{"year":2017,"count":2},{"year":2025,"count":2}],"oa_status":"green","license":"cc-by","oa_locations":[{"url":"https://figshare.com/articles/journal_contribution/Phase_II_study_of_two-weekly_temozolomide_in_patients_with_high-grade_gliomas/20913112","host_type":"repository"},{"url":"https://figshare.com/articles/journal_contribution/Phase_II_study_of_two-weekly_temozolomide_in_patients_with_high-grade_gliomas/20913112","host_type":"repository"},{"url":"https://api.elsevier.com/content/article/PII:S0967586805003395?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0967586805003395?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.jocn.2004.10.018","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/16356721","host_type":"repository"}],"fields_of_study":["Glioma Diagnosis and Treatment","Brain Metastases and Treatment","Meningioma and schwannoma management","Adult","Aged","Antineoplastic Agents, Alkylating","Dacarbazine","Dose-Response Relationship, Drug","Drug Administration Schedule","Drug Evaluation","Female","Glioma","Humans","Male","Middle Aged","Temozolomide","Time Factors","Treatment Outcome"],"mesh_terms":["Temozolomide","Adult","Aged","Dacarbazine","Dose-Response Relationship, Drug","Drug Administration Schedule","Drug Evaluation","Female","Glioma","Humans","Male","Middle Aged","Time Factors","Treatment Outcome","Antineoplastic Agents, Alkylating"],"keywords":["Temozolomide","Medicine","Chemotherapy","Phases of clinical research","Toxicity","Schedule","Internal medicine","Oncology","Dacarbazine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T01:35:29.301861Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}